Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2024 | $23.00 | Outperform | Oppenheimer |
| 11/20/2023 | Outperform | TD Cowen | |
| 7/6/2022 | $16.00 | Buy | Canaccord Genuity |
| 11/11/2021 | $25.00 → $19.00 | Outperform | SVB Leerink |
| 9/28/2021 | $16.00 | Neutral → Buy | Citigroup |
| 8/6/2021 | $29.00 → $25.00 | Outperform | SVB Leerink |
Oppenheimer initiated coverage of Harpoon Therapeutics with a rating of Outperform and set a new price target of $23.00
TD Cowen initiated coverage of Harpoon Therapeutics with a rating of Outperform
Canaccord Genuity resumed coverage of Harpoon Therapeutics with a rating of Buy and set a new price target of $16.00
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)